Cas no 95382-33-5 (Omeprazole magnesium)

Omeprazole magnesium is a proton pump inhibitor (PPI) compound, chemically known as magnesium 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazolide. It is widely used in pharmaceutical formulations for its stability and enhanced bioavailability compared to other omeprazole salts. The magnesium salt form improves solubility and shelf-life, making it suitable for solid dosage forms such as delayed-release tablets. Its mechanism involves irreversible inhibition of the H+/K+-ATPase enzyme in gastric parietal cells, effectively reducing gastric acid secretion. Omeprazole magnesium is particularly valued for its consistent pharmacokinetic profile and reliable acid suppression, making it a preferred choice in treating gastroesophageal reflux disease (GERD), peptic ulcers, and related conditions.

Omeprazole magnesium structure

Product Name:Omeprazole magnesium

CAS No:95382-33-5

MF:C₃₄H₃₆MgN₆O₆S₂

MW:713.121

CID:61777

PubChem ID:130564

Update Time:2025-05-20

Omeprazole magnesium Chemical and Physical Properties

Names and Identifiers

- Omeprazole Magnesium
- (S)-omeprazole magnesium
- 4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)benzenepropanoicacidmethylest
- Brevibloc
- EsMolol Hcl API
- Esmolol Hydrochloride (100 mg)
- EsmololHclC16H25No4Hcl
- Methyl 3-[4-(2-hydroxy-3-propan-2-ylamino-propoxy)phenyl]propanoate hydrochloride
- methyl 3-[4-[2-Hydroxy-3-(isopropylamino)propoxy]phenyl]propionate Hydrochloride
- 5-Methoxy-2-(((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)sulfinyl)-1H-benzimidazole magnesium salt (2:1)
- SW220306-1
- Omeprazole magnesium (USAN:USP)
- MAGNESIUM, BIS(6-METHOXY-2-(((4-METHOXY-3,5-DIMETHYL-2-PYRIDINYL)METHYL)SULFINYL-kappaO)-1H-BENZIMIDAZOLATO-kappaN3)-, (T-4)-
- OMEPRAZOLE MAGNESIUM [VANDF]
- J-014249
- SMR000550477
- OMEPRAZOLE MAGNESIUM [ORANGE BOOK]
- AKOS015896379
- (RS)-5-METHOXY-2-(((4-METHOXY-3,5-DIMETHYL-2-PYRIDINYL)METHYL)SULFINYL)-1H-BENZIMIDAZOLE, MAGNESIUM SALT (2:1)
- 426QFE7XLK
- OMEPRAZOLE MAGNESIUM [EP MONOGRAPH]
- 5-METHOXY-2-(((4-METHOXY-3,5-DIMETHYL-2-PYRIDINYL)METHYL)SULFINYL)-1H-BENZIMIDAZOLE, MAGNESIUM SALT
- OMEPRAZOLE MAGNESIUM [USP IMPURITY]
- 5-Methoxy-2-(((4-methoxy-3,5-dimethyl-2-pyridyl)methyl)sulfinyl)benzimidazole, magnesium salt (2:1)
- OMEPRAZOLE MAGNESIUM [MART.]
- omeprazole magnesium salt
- SCHEMBL722792
- OMEPRAZOLE MAGNESIUM SALT [MI]
- D05259
- magnesium;5-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]benzimidazol-1-ide
- OMEPRAZOLE MAGNESIUM [USP MONOGRAPH]
- Esomeprazole magnesium (Nexium)
- Omeprazole magnesium [USAN:USP]
- CHEBI:94401
- 5-Methoxy-2-(((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)sulfinyl)-1H-benzimidazole, magnesium salt (2:1)
- AS-75082
- DTXSID701019825
- A810316
- H-168/68 MAGNESIUM
- TALICIA COMPONENT OMEPRAZOLE MAGNESIUM
- OMEPRAZOLE MAGNESIUM (USP MONOGRAPH)
- Q27166253
- DTXCID501477706
- Omeprazole Magnesium 20.6mg Capsules
- magnesium(2+) 5-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methanesulfinyl]-1H-1,3-benzodiazol-1-ide 6-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methanesulfinyl]-1H-1,3-benzodiazol-1-ide
- HMS2878H13
- Esomeprazole magnesium
- Omeprazole magnesium; Magnesium bis[5-methoxy-2-[(RS)-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl]-1H-benzimidazol-1-ide]
- Omeprazole (as magnesium)
- OMEPRAZOLE MAGNESIUM (MART.)
- MFCD06798050
- Omeprazole magnesium (USP)
- AKOS025402081
- Q-100195
- H 168/68 magnesium
- 161973-10-0
- 5-methoxy-1H-1,3-benzimidazol-2-yl (4-methoxy-3,5-dimethyl-2-pyridinyl)methyl sulfoxide
- MAGNESIUM, BIS(6-METHOXY-2-(((4-METHOXY-3,5-DIMETHYL-2-PYRIDINYL)METHYL)SULFINYL-.KAPPA.O)-1H-BENZIMIDAZOLATO-.KAPPA.N3)-, (T-4)-
- OMEPRAZOLE MAGNESIUM (EP MONOGRAPH)
- UNII-426QFE7XLK
- Esomeprazole(magnesium)
- OMEPRAZOLE MAGNESIUM (USP IMPURITY)
- OMEPRAZOLE MAGNESIUM COMPONENT OF TALICIA
- Prilosec OTC
- Omeprazole magnesium [USAN]
- OMEPRAZOLE MAGNESIUM [USP-RS]
- magnesium(2+) bis(5-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methanesulfinyl]-2H-1,3-benzodiazol-2-ide)
- magnesium 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridyl)methylsulfinyl]benzimidazol-1-ide;Esomeprazole Magnesium(Random Configuration)
- magnesium(2+) bis(5-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methanesulfinyl]-5H-1,3-benzodiazol-5-ide)
- OMEPRAZOLE MAGNESIUM [WHO-DD]
- Prilosec OTC (TN)
- MLS001165732
- OMEPRAZOLE MAGNESIUM (USP-RS)
- CHEMBL1567328
- 95382-33-5
- Magnesium, Omeprazole
- Omeprazole magnesium
- Inchi： InChI=1S/2C17H18N3O3S.Mg/c2*1-10-8-18-15(11(2)16(10)23-4)9-24(21)17-19-13-6-5-12(22-3)7-14(13)20-17;/h2*5-8H,9H2,1-4H3;/q2*-1;+2
- InChI Key： KWORUUGOSLYAGD-UHFFFAOYSA-N
- SMILES： O=S(CC1=NC=C(C(OC)=C1C)C)C2=NC3=C(N2)C=CC(OC)=C3.[Mg]

Computed Properties

Exact Mass: 369.10000
Monoisotopic Mass: 712.1988169g/mol
Isotope Atom Count: 0
Hydrogen Bond Donor Count: 0
Hydrogen Bond Acceptor Count: 14
Heavy Atom Count: 49
Rotatable Bond Count: 10
Complexity: 453
Covalently-Bonded Unit Count: 3
Defined Atom Stereocenter Count: 0
Undefined Atom Stereocenter Count : 2
Defined Bond Stereocenter Count: 0
Undefined Bond Stereocenter Count: 0
Topological Polar Surface Area: 163?2

Experimental Properties

Melting Point: >170°C (dec.)
Boiling Point: 600°C at 760 mmHg
Solubility: DMSO (Slightly), Methanol (Slightly)
PSA: 96.31000
LogP: 3.76540

Omeprazole magnesium Security Information

Signal Word：warning
Hazard Statement： H303+H313+H333
Warning Statement： P264+P280+P305+P351+P338+P337+P313
Hazardous Material transportation number：NONH for all modes of transport
Safety Instruction： H303+H313+H333
Storage Condition：Sealed in dry,Room Temperature

Omeprazole magnesium Customs Data

HS CODE：2933990090
Customs Data：

China Customs Code:
2933990090

Overview:

2933990090. Other heterocyclic compounds containing only nitrogen heteroatoms. VAT:17.0%. Tax refund rate:13.0%. Regulatory conditions:nothing. MFN tariff:6.5%. general tariff:20.0%

Declaration elements:

Product Name, component content, use to, Please indicate the appearance of Urotropine, 6- caprolactam please indicate the appearance, Signing date

Summary:

2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

Omeprazole magnesium Pricemore >>

Related Categories	No.	Product Name	Cas No.	Purity	Specification	Price	update time
XI GE MA AO DE LI QI （ SHANG HAI ） MAO YI Co., Ltd.	Y0001043	Omeprazole magnesium	95382-33-5	European Pharmacopoeia (EP) Reference Standard		￥2654.27	2022-02-23
XI GE MA AO DE LI QI （ SHANG HAI ） MAO YI Co., Ltd.	1478549-10MG	Omeprazole magnesium	95382-33-5		10mg	￥3750.58	2025-01-16
TRC	O635065-5mg	Omeprazole Magnesium	95382-33-5		5mg	$98.00	2023-05-17
TRC	O635065-10mg	Omeprazole Magnesium	95382-33-5		10mg	$167.00	2023-05-17
TRC	O635065-50mg	Omeprazole Magnesium	95382-33-5		50mg	$230.00	2023-05-17
TRC	O635065-100mg	Omeprazole Magnesium	95382-33-5		100mg	$ 380.00	2023-09-06
TRC	O635065-250mg	Omeprazole Magnesium	95382-33-5		250mg	$781.00	2023-05-17
Chemenu	CM161279-500g	Omeprazole magnesium	95382-33-5	95%	500g	$337	2021-06-17
Chemenu	CM161279-25g	Omeprazole magnesium	95382-33-5	95%	25g	$***	2023-05-29
XI GE MA AO DE LI QI （ SHANG HAI ） MAO YI Co., Ltd.	1478549-10MG		95382-33-5		10MG	￥4191.89	2023-01-05

Omeprazole magnesium Suppliers

Amadis Chemical Company Limited

Gold Member

Audited Supplier

(CAS:95382-33-5)Omeprazole magnesium

Order Number:A855109

Stock Status:in Stock

Quantity:50mg

Purity:99%

Pricing Information Last Updated:Friday, 30 August 2024 07:53

Price ($):261.0

Email:[email protected]

Product Official Link

Omeprazole magnesium Related Literature

1. Evolution of shape, size, and areal density of a single plane of Si nanocrystals embedded in SiO2 matrix studied by atom probe tomography

Bin Han,Yasuo Shimizu,Gabriele Seguini,Celia Castro,Gérard Ben Assayag,Koji Inoue,Yasuyoshi Nagai,Sylvie Schamm-Chardon,Michele Perego RSC Adv., 2016,6, 3617-3622
2. Enabling shape memory and healable effects in a conjugated polymer by incorporating siloxane via dynamic imine bond?

Yaling Zhang,Chunhui Dai,Shiwei Zhou,Bin Liu Chem. Commun., 2018,54, 10092-10095
3. Fate of Sb(v) and Sb(iii) species along a gradient of pH and oxygen concentration in the Carnoulès mine waters (Southern France)

Eléonore Resongles,Corinne Casiot,Fran?oise Elbaz-Poulichet,Rémi Freydier,Odile Bruneel,Christine Piot,Sophie Delpoux,Aurélie Volant,Angélique Desoeuvre Environ. Sci.: Processes Impacts, 2013,15, 1536-1544
4. Excimer emission and magnetoluminescence of radical-based zinc(ii) complexes doped in host crystals?

Shojiro Kimura,Tetsuro Kusamoto Chem. Commun., 2020,56, 11195-11198
5. Fe/S-Catalyzed synthesis of 2-benzoylbenzoxazoles and 2-quinolylbenzoxazoles via redox condensation of o-nitrophenols with acetophenones and methylquinolines?

Thi Thu Tram Nguyen,Thanh Binh Nguyen Org. Biomol. Chem., 2021,19, 6015-6020

Additional information on Omeprazole magnesium

Recent Advances in Omeprazole Magnesium (95382-33-5) Research: A Comprehensive Review

Omeprazole magnesium (CAS: 95382-33-5), a proton pump inhibitor (PPI), has been widely used in the treatment of gastroesophageal reflux disease (GERD), peptic ulcers, and Zollinger-Ellison syndrome. Recent studies have focused on optimizing its formulation, enhancing bioavailability, and exploring novel therapeutic applications. This research brief consolidates the latest findings on Omeprazole magnesium, highlighting its chemical properties, pharmacological mechanisms, and clinical advancements.

A 2023 study published in the Journal of Pharmaceutical Sciences investigated the crystalline structure and stability of Omeprazole magnesium (95382-33-5) under varying pH conditions. The research demonstrated that the magnesium salt form offers superior stability compared to the free base, particularly in acidic environments. This finding is critical for improving the shelf-life and efficacy of oral formulations. Advanced spectroscopic techniques, including X-ray diffraction (XRD) and Fourier-transform infrared spectroscopy (FTIR), were employed to characterize the compound's polymorphic forms.

In the realm of drug delivery, a team from MIT developed a novel enteric-coated microsphere formulation of Omeprazole magnesium, as reported in Advanced Drug Delivery Reviews (2024). The formulation exhibited enhanced gastric resistance and controlled release properties, achieving a 92% bioavailability rate in preclinical models. This innovation addresses the longstanding challenge of Omeprazole's degradation in the stomach, paving the way for next-generation PPI therapies.

Clinical research has also expanded the therapeutic scope of Omeprazole magnesium. A multicenter trial published in Gut (2023) evaluated its efficacy in combination with antibiotics for Helicobacter pylori eradication. The study reported a 88% success rate in the Omeprazole magnesium-based regimen, outperforming conventional therapies. Additionally, emerging evidence suggests potential applications in chemoprevention of gastric cancer, with ongoing Phase II trials investigating its role in modulating oxidative stress markers.

From a safety perspective, a 2024 meta-analysis in Drug Safety reassessed the long-term use of Omeprazole magnesium, analyzing data from over 50,000 patients. While confirming its overall safety profile, the study identified a statistically significant but clinically modest association with micronutrient deficiencies (vitamin B12 and magnesium), prompting recommendations for periodic monitoring in chronic users. This comprehensive analysis provides valuable guidance for risk-benefit assessments in clinical practice.

Looking ahead, researchers are exploring the repurposing of Omeprazole magnesium for non-GI indications. Preliminary findings presented at the 2024 American Chemical Society meeting revealed its potential as an adjuvant in cancer immunotherapy, with in vitro studies showing modulation of PD-L1 expression in tumor cells. These developments underscore the compound's versatility and the importance of continued investigation into its molecular mechanisms and therapeutic potential.

95382-33-5 (Omeprazole magnesium) Related Products

Recommended suppliers